Sznol M - Search Results

1

Combination Strategies PD-1/PD-L1 Antagonists.

Sznol M. Sznol M. Cancer J. 2018 Jan/Feb;24(1):54-57. doi: 10.1097/PPO.0000000000000304. Cancer J. 2018. PMID: 29360729 Review.

2

Molecular markers of response to treatment for melanoma.

Sznol M. Sznol M. Cancer J. 2011 Mar-Apr;17(2):127-33. doi: 10.1097/PPO.0b013e318212dd5a. Cancer J. 2011. PMID: 21427556 Review.

3

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Sznol M, Chen L. Sznol M, et al. Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.

4

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.

Sznol M. Sznol M. Cancer J. 2014 Jul-Aug;20(4):290-5. doi: 10.1097/PPO.0000000000000056. Cancer J. 2014. PMID: 25098290 Review.

5

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.

Sznol M, Chen L. Sznol M, et al. Clin Cancer Res. 2013 Oct 1;19(19):5542. doi: 10.1158/1078-0432.CCR-13-2234. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048329 Free PMC article. No abstract available.

6

Challenges in Conducting Clinical Research on Patients With Advanced Melanoma.

Sznol M. Sznol M. Cancer J. 2017 Jan/Feb;23(1):75-78. doi: 10.1097/PPO.0000000000000239. Cancer J. 2017. PMID: 28114259 Review.

7

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. Kluger HM, et al. Among authors: sznol m. Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21. Clin Cancer Res. 2017. PMID: 28223273 Free PMC article.

8

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL. Smithy JW, et al. Among authors: sznol m. J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28331615 Free PMC article.

9

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.

Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: sznol m. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.

10

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A. Davar D, et al. Among authors: sznol m. J Immunother Cancer. 2024 Aug 3;12(8):e009474. doi: 10.1136/jitc-2024-009474. J Immunother Cancer. 2024. PMID: 39097413 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters